Insider Selling: Adherex Technologies (NASDAQ:FENC) Director Sells 10,349 Shares of Stock

Adherex Technologies Inc. (NASDAQ:FENC) Director Rosty Raykov sold 10,349 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total transaction of $80,308.24. Following the transaction, the director directly owned 98,477 shares of the company’s stock, valued at $764,181.52. This represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Friday, December 5th, Rosty Raykov sold 10,000 shares of Adherex Technologies stock. The stock was sold at an average price of $7.54, for a total value of $75,400.00.
• On Wednesday, November 5th, Rosty Raykov sold 10,000 shares of Adherex Technologies stock. The shares were sold at an average price of $8.10, for a total value of $81,000.00.

Adherex Technologies Stock Up 3.2%

Shares of NASDAQ FENC traded up $0.24 during midday trading on Monday, reaching $7.83. 134,027 shares of the stock were exchanged, compared to its average volume of 116,975. The firm has a market cap of $267.50 million, a price-to-earnings ratio of -34.04 and a beta of 0.78. The firm has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $8.28. Adherex Technologies Inc. has a twelve month low of $4.68 and a twelve month high of $9.92.

Adherex Technologies (NASDAQ:FENC) last posted its earnings results on Thursday, November 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.06. The firm had revenue of $12.46 million during the quarter, compared to analyst estimates of $13.43 million. Research analysts expect that Adherex Technologies Inc. will post -0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Adherex Technologies

An institutional investor recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies at the end of the most recent reporting period. 55.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on FENC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Adherex Technologies from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 17th. Zacks Research upgraded Adherex Technologies from a “strong sell” rating to a “hold” rating in a report on Friday, December 12th. Finally, Piper Sandler assumed coverage on Adherex Technologies in a report on Friday, January 9th. They set an “overweight” rating and a $18.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adherex Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.